Clinical Trial Update: Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating concurrent carboplatin with reduced-dose craniospinal irradiation for metatstic medulloblastoma and high-risk supratentorial PNET has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma
• Primitive Neuroectodermal Tumor

Drugs mentioned

• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Metastatic Medulloblastoma, High Risk Supratentorial PNET | Phase 2 | Status: COMPLETED | Results posted: 2022-01-11